Danske Bank A/S Ligand Pharmaceuticals Inc Transaction History

Danske Bank A/S

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 19, 2025	BUY	$112.56 - $177.14 $11,256 - $17,714	100 New	100 $17,000
Q2 2025 Dec 18, 2025	SELL	$96.67 - $118.22 $1.33 Million - $1.63 Million	-13,779 Reduced 98.92%	151 $17,000
Q1 2025 Dec 18, 2025	BUY	$105.14 - $122.23 $1.45 Million - $1.69 Million	13,830 Added 13830.0%	13,930 $1.46 Million

342

20.5M

19K

11.5K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $3.39B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Danske Bank A/S, based on Form 13F filings with the SEC.

Stay updated on Danske Bank A/S with notifications on news.